Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis
- 16 July 2009
- journal article
- letter
- Published by Springer Nature in Zeitschrift für Neurologie
- Vol. 256 (10) , 1771-1772
- https://doi.org/10.1007/s00415-009-5200-9
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- More on Melanoma with TransdifferentiationNew England Journal of Medicine, 2008
- Melanoma Complicating Treatment with Natalizumab for Multiple SclerosisNew England Journal of Medicine, 2008
- Alpha4-integrin antagonism — an effective approach for the treatment of inflammatory diseases?Drug Discovery Today, 2007
- Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple SclerosisArchives of Neurology, 2006
- Regulation of Integrin Activity by MIAJournal of Biological Chemistry, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab and Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2005
- Comparative Epidemiology and Pathogenic Factors for Nonmelanoma Skin Cancer in Organ Transplant PatientsDermatologic Surgery, 2004
- Expression of the integrin $alpha;4$beta;1 on melanoma cells can inhibit the invasive stage of metastasis formationCell, 1994